Transfer pricing and book-profit principles shaped treatment of capital advances, contract manufacturing margins, and statutory deductions.

Transfer pricing treatment turned on the real character of the transactions: share application money to a wholly owned foreign subsidiary and optionally fully convertible debentures were held to retain capital character, so notional interest adjustments were deleted. For Pantoprazole sales, TNMM was accepted over Profit Split Method because the assessee functioned as a contract manufacturer while the associated enterprise owned the key intangibles and entrepreneurial risks. The ruling also addressed weighted deduction for research-related expenditure, book-profit computation under section 115JB, exclusion of partnership remuneration from book profit, section 14A adjustments, capital treatment of one repair item, and allowance of deduction for a captive power plant.

---

---

Issues: (i) whether notional interest could be added on share application money advanced to a wholly owned foreign subsidiary; (ii) whether notional interest could be imputed on Optionally Fully Convertible Debentures before conversion into equity; (iii) whether corporate guarantee commission adjustment required fresh adjudication; (iv) whether Transactional Net Margin Method or Profit Split Method was the most appropriate method for pricing Pantoprazole sales and whether the corresponding transfer pricing addition survived; (v) whether weighted deduction under section 35(2AB) could be denied on trademark, product registration, advertisement and related R&D expenditure; (vi) whether remuneration received from the partnership firm could be excluded from book profit under section 115JB or re-characterised as royalty; (vii) whether disallowance under section 14A was to be added while computing book profit under section 115JB; (viii) whether additions on sales to the partnership firm, disallowance of expenses incurred on its behalf, treatment of repair expenditure as capital, and deduction under section 80-IA(4) were sustainable.

Issue (i): whether notional interest could be added on share application money advanced to a wholly owned foreign subsidiary

Analysis: The advance was towards equity subscription and the subsidiary was wholly owned. The delay in allotment did not alter the character of the transaction into a loan. The relevant Indian company law provisions were held inapplicable to the foreign subsidiary, and the transaction remained capital in nature. Re-characterisation solely because of delayed allotment was rejected.

Conclusion: The addition of notional interest on share application money was deleted in favour of the assessee.

Issue (ii): whether notional interest could be imputed on Optionally Fully Convertible Debentures before conversion into equity

Analysis: The debentures were hybrid capital instruments with conversion into equity in later years and were issued on beneficial terms. The Court followed the earlier years' decision in the assessee's own case and declined to depart from it. The Revenue's attempt to treat the instrument as debt for the interim period was not accepted.

Conclusion: The notional interest adjustment on OFCDs was deleted in favour of the assessee.

Issue (iii): whether corporate guarantee commission adjustment required fresh adjudication

Analysis: The issue was not finally decided on merits in the present year and was directed to be decided afresh in accordance with the jurisdictional High Court's decision after giving adequate hearing. The matter was therefore not concluded on merits in this appeal.

Conclusion: The issue was remanded and allowed for statistical purposes.

Issue (iv): whether Transactional Net Margin Method or Profit Split Method was the most appropriate method for pricing Pantoprazole sales and whether the corresponding transfer pricing addition survived

Analysis: The assessee was held to be a contract manufacturer. The ownership of the relevant IPR/ANDA and the entrepreneurial risks lay with the associated enterprise, while the assessee performed only manufacturing. On the facts, the controlled transaction did not involve such integrated functions or unique contributions as would justify Profit Split Method. TNMM, supported by comparable margins and the commercial reality of the arrangement, was accepted as the most appropriate method. The transfer pricing authorities were not permitted to re-characterise the transaction contrary to its substance.

Conclusion: The Profit Split Method adjustment was rejected and the transfer pricing addition on Pantoprazole sales was deleted in favour of the assessee.

Issue (v): whether weighted deduction under section 35(2AB) could be denied on trademark, product registration, advertisement and related R&D expenditure

Analysis: These expenses were treated as relatable to the approved research and development activity and the same controversy had already been resolved in the assessee's favour in earlier years. Following the principle of consistency, the disallowance could not be sustained merely by re-characterising the nature of the expenditure.

Conclusion: The denial of weighted deduction was set aside and the deduction was allowed in favour of the assessee.

Issue (vi): whether remuneration received from the partnership firm could be excluded from book profit under section 115JB or re-characterised as royalty

Analysis: Book profit under section 115JB is computed strictly in accordance with the statutory Explanation. Remuneration received from the firm was not covered by the specific exclusion for income under section 10(2A). At the same time, the attempt to re-characterise the remuneration as royalty was rejected because the payment arose from the partnership arrangement and the corresponding profit was otherwise exempt in the hands of the partner. The amount could not be recast as royalty on assumptions.

Conclusion: Exclusion from book profit was denied, but re-characterisation as royalty was disapproved.

Issue (vii): whether disallowance under section 14A was to be added while computing book profit under section 115JB

Analysis: Following binding jurisdictional precedent, expenditure relatable to exempt income disallowed under section 14A was held to fall within the adjustments contemplated by section 115JB for book profit computation.

Conclusion: The addition was deleted in favour of the assessee.

Issue (viii): whether additions on sales to the partnership firm, disallowance of expenses incurred on its behalf, treatment of repair expenditure as capital, and deduction under section 80-IA(4) were sustainable

Analysis: The sales-price adjustment to the partnership firm was rejected, as was the disallowance of expenses incurred on its behalf. The repair item of Rs. 10,17,500 was treated as capital expenditure, while the remaining repair-related deletion was upheld. The claim for deduction under section 80-IA(4) for the captive power plant was accepted.

Conclusion: The sales-price and section 37 disallowances were deleted, the capital treatment of Rs. 10,17,500 was sustained, and the section 80-IA(4) deduction was allowed in favour of the assessee.

Final Conclusion: The Revenue's appeal was dismissed and the assessee's appeal was partly allowed, with the principal transfer pricing additions on share application money, OFCDs and Pantoprazole sales deleted, several statutory deductions granted, one repair item sustained as capital expenditure, and a few issues remanded or rejected on book-profit computation.

Ratio Decidendi: In transfer pricing, the controlled transaction must be assessed according to its real commercial character and functional profile, and a contract manufacturer performing only routine manufacturing functions cannot be subjected to profit split or re-characterisation where the associated enterprise owns the key intangibles and bears the entrepreneurial risks; statutory book-profit adjustments under section 115JB, however, must strictly follow the specific items enumerated in the provision.

---